Genetics of Mucopolysaccharidosis Type I Follow-up
- Author: Maryam Banikazemi, MD; Chief Editor: Bruce Buehler, MD more...
Further Outpatient Care
Because of progressive nature of mucopolysaccharidosis type I (MPS I), these patients need to be regularly monitored. The focus of these evaluations should be to identify potential problems early at a time when intervention would decrease morbidity, prevent premature mortality, and enhance the quality of life. Every patient with MPS I is unique; however, a general schedule of assessment and follow-up is available through the MPS I registry.
Prognosis
MPS IH/S is an intermediate form. Symptoms tend to develop during the late teenage years to the early 20s and are milder than the symptoms observed in Hurler syndrome.
Patient Education
Genetic counseling should be provided to families to explain autosomal recessive inheritance. Organizations and support groups for patients and families affected by MPS disorders include the following:
Yano S, Moseley K, Pavlova Z. Postmortem studies on a patient with mucopolysaccharidosis type I: Histopathological findings after one year of enzyme replacement therapy. J Inherit Metab Dis. Mar 27 2009;[Medline].
Moore D, Connock MJ, Wraith E, Lavery C. The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis. Sep 16 2008;3:24. [Medline].
D'Aco K, Underhill L, Rangachari L, Arn P, Cox GF, Giugliani R, et al. Diagnosis and treatment trends in mucopolysaccharidosis I: findings from the MPS I Registry. Eur J Pediatr. Jan 11 2012;[Medline].
Pastores GM. Musculoskeletal complications encountered in the lysosomal storage disorders. Best Pract Res Clin Rheumatol. Oct 2008;22(5):937-47. [Medline].
Müller KB, Pereira VG, Martins AM, D'Almeida V. Evaluation of a-iduronidase in dried blood spots is an accurate tool for mucopolysaccharidosis I diagnosis. J Clin Lab Anal. 2011;25(4):251-4. [Medline].
Cunningham M, Cox EO. Hearing assessment in infants and children: recommendations beyond neonatal screening. Pediatrics. Feb 2003;111(2):436-40. [Medline].
Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics. Jan 2009;123(1):19-29. [Medline].
Clarke LA, Wraith JE, Beck M, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. Jan 2009;123(1):229-40. [Medline].
Giugliani R, Rojas VM, Martins AM, et al. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I. Mol Genet Metab. Jan 2009;96(1):13-9. [Medline].
Pastores GM. Laronidase (Aldurazyme): enzyme replacement therapy for mucopolysaccharidosis type I. Expert Opin Biol Ther. Jul 2008;8(7):1003-9. [Medline].
de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, et al. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. Aug 10 2011;6:55. [Medline]. [Full Text].
Arn P, Wraith JE, Underhill L. Characterization of Surgical Procedures in Patients with Mucopolysaccharidosis Type I: Findings from the MPS I Registry. J Pediatr. Feb 11 2009;[Medline].
Herrero R, Brinton LA, Reeves WC, Brenes MM, de Britton RC, Tenorio F, et al. Injectable contraceptives and risk of invasive cervical cancer: evidence of an association. Int J Cancer. Jul 15 1990;46(1):5-7. [Medline].
Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly W, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. Vol 3. 8th ed. New York, NY: McGraw Hill; 2001:3421-52.

